Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Conclusions This study successfully identified the MTD and DLTs for NMS-1286937 and characterized its safety profile.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research